CRDF Beats Q2 EPS, Sales Estimates

Cardiff Oncology (NASDAQ: CRDF ) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent.

This is a 33.33 percent increase over losses of $(0.21) per share from the same period last year.

The company reported quarterly sales of $104.000 thousand which beat the analyst consensus estimate of $70.714 thousand by 47.07 percent.

This is a 14.05 percent decrease over sales of $121.000 thousand the same period last year.